期刊文献+
共找到9篇文章
< 1 >
每页显示 20 50 100
核偏最小二乘法及其在P-glycoprotein抑制剂设计中应用 被引量:1
1
作者 李燕 王永华 张述伟 《大连理工大学学报》 EI CAS CSCD 北大核心 2008年第5期636-640,共5页
介绍了一个新的基于优化推导出的核偏最小二乘(kernel partial least squares,K-PLS)的算法原理和实现步骤,并且给出了利用K-PLS法构建P-糖蛋白(P-glycoprotein,P-gp)黄酮类抑制剂的定量构效关系(QSAR)模型.利用该方法结合几个简单的分... 介绍了一个新的基于优化推导出的核偏最小二乘(kernel partial least squares,K-PLS)的算法原理和实现步骤,并且给出了利用K-PLS法构建P-糖蛋白(P-glycoprotein,P-gp)黄酮类抑制剂的定量构效关系(QSAR)模型.利用该方法结合几个简单的分子拓扑参数,构建了具有高准确率的预测模型.该模型将有助于P-gp黄酮类抑制剂的虚拟筛选和理性设计.结果证明K-PLS是一个十分稳定可靠的方法,将会在化学计量学领域得到较好的应用和推广. 展开更多
关键词 核偏最小二乘 QSAR p-glycoprotein 抑制剂
在线阅读 下载PDF
P-glycoprotein的新功能在肿瘤研究中的进展 被引量:2
2
作者 张飞 牛瑞芳 《中国肿瘤临床》 CAS CSCD 北大核心 2015年第12期632-636,共5页
肿瘤多药耐药性(multiple drug resistance,MDR)的发生往往伴随着多药耐药基因如MDR1、MRP1和BCRP等高表达,其中MDR1基因编码的P-糖蛋白(P-glycoprotein,P-gp)是目前公认可以诱发癌细胞发生MDR的重要分子。传统研究认为P-gp主要是作为... 肿瘤多药耐药性(multiple drug resistance,MDR)的发生往往伴随着多药耐药基因如MDR1、MRP1和BCRP等高表达,其中MDR1基因编码的P-糖蛋白(P-glycoprotein,P-gp)是目前公认可以诱发癌细胞发生MDR的重要分子。传统研究认为P-gp主要是作为一个药物泵将化疗药物从细胞内排出从而导致MDR。然而系列研究发现,除了介导MDR以外,P-gp还能够调节癌细胞的生长、增殖、凋亡、迁移和侵袭等其他生物学行为;而且研究表明P-gp的这些作用可以依赖,也可以不依赖于其药物泵的功能。这些结果表明P-gp能够通过一些新的机制促进肿瘤的进展。本文主要针对P-gp在促进肿瘤进展中的作用进行综述。 展开更多
关键词 p-glycoprotein 多药耐药 增殖凋亡迁移上皮间质转化血管生成
在线阅读 下载PDF
多药耐药相关蛋白和P-糖蛋白在口腔鳞癌中的表达及其对新辅助化疗敏感性的预测研究 被引量:4
3
作者 杨凯 陈睿 +2 位作者 孙德平 张国栋 梅杰 《重庆医科大学学报》 CAS CSCD 2008年第8期931-933,1015,共4页
目的:探讨新辅助化疗前后P-糖蛋白(P-glycoprotein,P-pg)和多药耐药相关蛋白1(Multiple resistance-associated protein-1,MRP1)在口腔鳞癌组织中的表达及其与化疗敏感性和相关临床病理因素的关系。方法:采用SP免疫组化法,对106例口腔... 目的:探讨新辅助化疗前后P-糖蛋白(P-glycoprotein,P-pg)和多药耐药相关蛋白1(Multiple resistance-associated protein-1,MRP1)在口腔鳞癌组织中的表达及其与化疗敏感性和相关临床病理因素的关系。方法:采用SP免疫组化法,对106例口腔鳞癌患者新辅助化疗前后P-pg和MRP1的表达水平进行检测,分析其表达水平与化疗疗效的关系。结果:(1)化疗后口腔鳞癌组织中P-pg阳性表达率为74.53%,显著高于化疗前41.51%(P﹤0.05);化疗前P-pg表达阴性患者有效率为56.45%,显著高于P-pg表达阳性患者的有效率34.09%(P﹤0.05);P-pg的表达水平与口腔鳞癌的分化程度呈正相关(P﹤0.05),但与临床分期和是否有颈淋巴结转移不相关(P﹥0.05);(2)MRP1在口腔鳞癌组织中的阳性表达率在化疗前后分别为49.06%、57.55%,两者间无显著性差异(P﹥0.05);化疗前MRP1表达阴性患者和阳性患者的有效率分别为50.00%、44.23%,两者间无显著性差异(P﹥0.05);MRP1的表达水平与口腔鳞癌的分化程度、临床分期和颈淋巴结转移均不相关(P﹥0.05)。结论:P-pg和MRP1在口腔鳞癌组织中均有较高的表达水平,但只有P-pg的表达水平与新辅助化疗疗效具有显著的相关性,认为P-pg的表达水平可作为预测口腔鳞癌对化疗敏感性的分子标记物。 展开更多
关键词 新辅助化疗 多药耐药相关蛋白 P-糖蛋白 口腔鳞癌
在线阅读 下载PDF
PI3K特异性抑制剂LY294002对卵巢癌紫杉醇耐药细胞株逆转作用的研究 被引量:4
4
作者 袁犁 周琦 +3 位作者 徐发良 李少林 甘霖 邹冬玲 《中国肿瘤临床》 CAS CSCD 北大核心 2012年第6期301-304,共4页
目的:研究磷脂酰肌醇-3-激酶(P13K)特异性抑制剂LY294002对卵巢癌紫杉醇耐药细胞株(A2780/Taxo1)多药耐药逆转的影响。方法:将P13K特异性抑制剂LY294002处理卵巢癌紫杉醇耐药细胞24 h后,用CCK-8(Cell CountingKit-8)法检测细胞的增殖速... 目的:研究磷脂酰肌醇-3-激酶(P13K)特异性抑制剂LY294002对卵巢癌紫杉醇耐药细胞株(A2780/Taxo1)多药耐药逆转的影响。方法:将P13K特异性抑制剂LY294002处理卵巢癌紫杉醇耐药细胞24 h后,用CCK-8(Cell CountingKit-8)法检测细胞的增殖速度、对紫杉醇敏感性的分析;采用流式细胞技术检测细胞周期和凋亡。应用Western blot检测细胞中P-glycoprotein(P-gP)、Akt和p-Akt蛋白的表达情况。结果:用LY294002处理A2780/Taxol细胞后细胞增殖速度变慢、对紫杉醇的半数抑制浓度(IC_(50))降低。实验组和对照组细胞的凋亡率分别是(2.64±0.90)%和(10.98±1.16)%(P<0.05)。LY294002处理后的Go/G,期细胞增加,S期明显减少,差异有统计学意义(P<0.05)。LY294002处理后的细胞与对照组相比P-gP和p-Akt的蛋白表达降低。结论:LY294002能够有效的逆转卵巢癌紫杉醇耐药细胞A2780/Taxol产生的多药耐药。 展开更多
关键词 LY294002 PI3K/Akt p-glycoprotein 卵巢癌 紫杉醇
在线阅读 下载PDF
CD44V6、P-gp、Top-Ⅱ在结直肠癌中的表达与临床病理的关系及其临床意义 被引量:8
5
作者 王欣 傅仲学 《重庆医科大学学报》 CAS CSCD 北大核心 2011年第2期163-167,共5页
目的:探讨CD44拼接变异体V6(CD44variantV6,CD44V6)、P-糖蛋白(P-glycoprotein,P-gp)、拓扑异构酶Ⅱ(TopoisomeraseⅡ,Top-Ⅱ)在结直肠中表达及其临床意义。方法:采用HE方法验证结直肠癌组织和正常大肠黏膜组织。采用免疫组织化学法MaxV... 目的:探讨CD44拼接变异体V6(CD44variantV6,CD44V6)、P-糖蛋白(P-glycoprotein,P-gp)、拓扑异构酶Ⅱ(TopoisomeraseⅡ,Top-Ⅱ)在结直肠中表达及其临床意义。方法:采用HE方法验证结直肠癌组织和正常大肠黏膜组织。采用免疫组织化学法MaxVision二步法检测80例结直肠癌组织及46例正常大肠黏膜组织中CD44V6、P-gp、Top-Ⅱ蛋白的表达情况,将其与性别,临床Dukes分期,浸润深度,淋巴转移等临床病理学资料进行统计学分析。结果:CD44V6、P-gp、Top-Ⅱ蛋白在结直肠癌组织中的表达显著高于正常大肠黏膜组织。CD44V6在结直肠癌中的表达强度与肿瘤的临床Dukes分期(rs=0.328,P<0.05),浸润深度(rs=0.356,P<0.01),淋巴转移(rs=0.406,P<0.01)成显著正相关性,与性别无相关性;P-gp在结直肠癌中的表达强度与性别,临床Dukes分期,肿瘤的浸润深度,淋巴转移无相关性。Top-Ⅱ在结直肠癌中的表达强度与性别,临床Dukes分期,肿瘤的浸润深度无相关性,但与淋巴转移有相关性(rs=0.245,P<0.05)。结论:P-gp、Top-Ⅱ、CD44V6在结直肠癌中均高表达。CD44V6在结直肠癌中的表达与临床Dukes分期,肿瘤的浸润深度及淋巴转移情况存在正相关性。 展开更多
关键词 CD44 variant V6 p-glycoprotein TopoisomeraseⅡ 结直肠癌
在线阅读 下载PDF
Transport and uptake of clausenamide enantiomers in CYP3A4-transfected Caco-2 cells: an insight into the efflux-metabolism alliance 被引量:1
6
《中国药理学通报》 CAS CSCD 北大核心 2015年第B11期211-211,共1页
Aim The present study developed a CYP3A4-expressed Caco-2 monolayer model at which effects of the efflux-metabolism alliance on the transport and uptake of clausenamide(CLA) enantiomers as CYP3A4 substrates were inv... Aim The present study developed a CYP3A4-expressed Caco-2 monolayer model at which effects of the efflux-metabolism alliance on the transport and uptake of clausenamide(CLA) enantiomers as CYP3A4 substrates were investigated. The apparent permeability coefficients (Papp) of ( - ) and ( + )CLA were higher in the ab- sorptive direction than those in the secretory direction with efflux ratios(ER) of 0. 709 ± 0.411 and 0. 867± 0. 250 ( Х10^-6 -1 cm · s ), respectively. Their bidirectional transports were significantly reduced by (75.6 ± 87.5)% af- ter treatment with verapamil ( a P-glycoprotein inhibitor) that increased the rate of metabolism by CYP3 A4, whereas the CYP3A4 inhibitor ketoconazole treatment markedly enhanced the basolateral to apical flux of ( - ) and ( + ) CLA with ERs being 2. 934 ± 1. 432 and 1. 877 ± 0. 148 ( Х 10^-6 cm/s) respectively. These changes could be blocked by the duel CYP3A4/P-glycoprotein inhibitor cyclosporine A, consequently, Papp values for CLA enanti- omers in both directions were significantly greater than those obtained by using verapamil or ketoconazole, and their ERs were similar to those following ( - ) or ( + )-isomer treatment alone. Furthermore, the uptake of ( - )CLA was more than that of ( + )CLA in the transfected cells. Incubation with ketoeonazole decreased the intracellular concentrations of the two enantiomers. This effect disappeared in the presence of a CYP3A4 inducer dexametha- sone. These results indicated that CYP3A4 could influence P-gp efflux, transport and uptake of CLA enantiomers as CYP3A4 substrates and that a duel inhibition to CYP3A4/ P-glycoprotein could enhance their absorption and bioavailability, which provides new insight into the efflux-metabolism alliance and will benefit the clinical pharma- cology of (?) CLA as a candidate drug for treatment of Alzheimer' s disease. 展开更多
关键词 CLAUSENAMIDE ENANTIOMERS CYTOCHROME P450 3A4 p-glycoprotein CACO-2 cell line
在线阅读 下载PDF
Absorption characteristic of Paeoniflorin-6'O-benzene sulfonate in an situ single-pass intestinal perfusion model
7
《中国药理学通报》 CAS CSCD 北大核心 2015年第B11期215-215,共1页
Aim Paeoniflorin-6'O-benzene sulfonate (CP-25) was synthesized to improve oral absorption. This study was performed to investigate absorptive behavior and mechanism of CP-25 in intestine. Methods The effects of dru... Aim Paeoniflorin-6'O-benzene sulfonate (CP-25) was synthesized to improve oral absorption. This study was performed to investigate absorptive behavior and mechanism of CP-25 in intestine. Methods The effects of drug concentration, intestinal segments, gender as well as ATP binding cassette (ABC) transporter inhibitors on absorption of CP-25 were studied in a situ single-pass intestinal perfusion rat model. Meanwhile, Paeoniflorin (Pae) was tested and served as control group. The concentration of tested drugs was measured by HPLC. Results The results showed intestinal absorption of CP-25 was neither segmental dependent changes nor gender difference. Transepithelial transportation would not change with increasing concentrations of CP-25, which suggest a passive transport was the main pattern of CP-25. Additionally, absorption of CP-25 was much better than that of Pae in small intestine. When compared with Pae, CP-25 gave a 1.82-fold permeability rate. Finally, the results indicated Pae was substrate of P-glycoprotein (P-gp) , but was not the substrate of breast cancer resistance protein and muhi- drug resistance associated protein 2. Among the used ABC inhibitors, the absorption rate of Pae could only be in- creased by? P-gp inhibitor Verapamil and GF120918, while CP-25 had no remarkable alteration. Conclusion CP-25 has better absorptive features than that of Pae, which may be attributed to its lipophicity enhancement and be unaffected by P-gp efflux. 展开更多
关键词 PAEONIFLORIN Paeoniflorin-60-benzene SULFONATE single-pass intestinal peffusion p-glycoprotein
在线阅读 下载PDF
Mechanisms of imperatorin on regulating Pglycoprotein in blood-brain barrier based on network pharmacology and in vitro experiment
8
作者 SONG Yizhen YIN Wanxin +5 位作者 MA Yicong AN Yufan HUANG Jiaqi YAN Zhongjie WU Xiuwen WANG Yuanyu 《中国药理学与毒理学杂志》 CAS 北大核心 2023年第S01期17-18,共2页
OBJECTIVE To explore mecha⁃nisms of imperatorin on regulating P-glycoprotein(P-gp)in blood-brain barrier(BBB)based on net⁃work pharmacology combined with in vitro experi⁃ment.METHODS Drug targets were predicted using ... OBJECTIVE To explore mecha⁃nisms of imperatorin on regulating P-glycoprotein(P-gp)in blood-brain barrier(BBB)based on net⁃work pharmacology combined with in vitro experi⁃ment.METHODS Drug targets were predicted using the Pharmapper and Swiss targets data⁃bases;disease targets were obtained through the Genecards database;intersections between drugs and disease targets were screened by Cytoscape software;the obtained core targets were used to construct protein-protein interaction(PPI)network,gene ontology(GO)functions,and Kyoto encyclopedia of genes and genomes(KEGG)pathway enrichment analysis.The effects of imperatorin(20,50,100μmol·L^(-1))on P-gp activity were monitored in hCMEC/D3 in vitro BBB model,and the effects of imperatorin on the expression of target proteins were verified using Western blot method.RESULTS 55 drug targets and 3102 disease targets were obtained from the network pharmacology screening,and 37 core targets were obtained after the combination.Enrichment analysis showed that core targets were closely related to chemical synaptic trans⁃mission regulation,neurotransmitter receptor activity,protein kinase regulation activity,G proteincoupled receptor signaling pathway,neural active ligand receptor interaction pathway,PI3K-Akt sig⁃naling pathway,VEGF signaling pathway,etc..In vitro experimental validation suggested that all tested concentration groups of imperatorin signifi⁃cantly reduced the activity and expression of P-gp,which were achieved by significantly downregu⁃lating the phosphorylation levels of PI3K and Akt,and repressing the expression of VEGFR2 pro⁃tein.CONCLUSION Network pharmacology was used to predict the core targets and signaling pathways of imperatorin on regulating P-gp in BBB and relevant validation was conducted through in vitro experiments,providing a refer⁃ence basis for further exploration of the mecha⁃nisms of imperatorin on regulating P-gp in BBB. 展开更多
关键词 IMPERATORIN blood-brain barrier p-glycoprotein network pharmacology in vitro experiment
在线阅读 下载PDF
Reversal Effects of Ivermectin and Moxidectin on Multidrug Resistance in C6/adr Cells in vitro
9
作者 Chen Chen Liang Hong-sheng +2 位作者 Wang Li-wei Wang Qing Gao Ai-li 《Journal of Northeast Agricultural University(English Edition)》 CAS 2021年第3期48-57,共10页
Multidrug resistance(MDR)is a serious obstacle encountered in cancer treatment.This study was performed to explore the reversal MDR activity of ivermectin(IVM)from avermectin family and moxidectin(MOX)belonging to mil... Multidrug resistance(MDR)is a serious obstacle encountered in cancer treatment.This study was performed to explore the reversal MDR activity of ivermectin(IVM)from avermectin family and moxidectin(MOX)belonging to milbemycin family.The two compounds(5μmol•L-1)showed strong potency to increase adriamycin cytotoxicity toward adriamycin-resistant rat glioma cells C6/adr with fold reversal(FR)of 31.02 and 13.40,respectively.In addition,the mechanisms of them on p-glycoprotein(P-gp)-mediated MDR demonstrated that the two compounds significantly increased the intracellular accumulations of adriamycin and Rh123 via inhibiting P-gp efflux.Based on the analysis of P-gp,MDR1 and MRP1 gene expressions by using immunofluorescence flow cytometry and RT-PCR,the results revealed that the two compounds could down regulate the expression of P-gp,and that MDR1 and MRP1 gene expressions were down regulated.These findings suggested that ivermectin and moxidectin probably represented potent agents for reversing MDR in cancer therapy,and especially ivermectin was a better modulator. 展开更多
关键词 IVERMECTIN MOXIDECTIN C6/adr multidrug resistance p-glycoprotein
在线阅读 下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部